GlassScriptPhysician profile
Yamily Moreno
NPI 1134698780
$2,786.09
in general payments reported to CMS, 2019-2025
21 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $830 · 2022: $768 · 2023: $680 · 2024: $351 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $407.74 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.75 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $225.56 | 2021-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.31 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $208.47 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Alkermes, INC. | $206.23 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $204.34 | 2021-2024 | |
| Lundbeck LLC | $171.69 | 2021-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $159.62 | 2022-2025 | Rexulti |
| Tris Pharma INC | $135.99 | 2022-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $129.04 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $92.90 | 2021-2023 | Belsomra |
| Eisai INC. | $88.12 | 2021 | |
| Axsome Therapeutics, INC. | $78.35 | 2023-2024 | Auvelity |
| Corium, LLC | $76.55 | 2021-2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $44.71 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $36.42 | 2023 | Fanapt, Hetlioz |
| Neuronetics, INC. | $26.11 | 2022 | |
| Neurocrine Biosciences, INC. | $18.72 | 2022 | |
| Indivior INC. | $16.33 | 2023 | Sublocade |
| Novo Nordisk INC | $15.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yamily Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.